Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)
September 11, 2026
A Single-arm, Open-label, Phase 2 Study of Subcutaneous Isatuximab via On-Body Delivery System with Weekly Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)